Low-Level Laser Therapy (LLLT) and Hidradenitis Suppurativa
Photobiomodulation: Evidence, Mechanisms, and Clinical Protocols
Low-level laser therapy is one of the more evidence-supported emerging therapies for HS, with multiple small controlled studies demonstrating measurable reductions in lesion counts. This page provides a thorough, balanced review of what LLLT is, how it works at the cellular level, what research currently shows, and what patients need to know before pursuing it.
What Low-Level Laser Therapy Is
Low-Level Laser Therapy (LLLT), also called photobiomodulation (PBM), is a form of light therapy that uses low-power lasers or light-emitting diodes (LEDs) at specific wavelengths to deliver therapeutic energy to tissue. Unlike surgical or ablative lasers that cut or destroy tissue, LLLT operates at power levels too low to cause thermal damage. Instead, it stimulates biological processes at the cellular level.
The therapeutic wavelengths used in LLLT fall primarily within the "optical window" of tissue - the range where light can penetrate skin most effectively without being absorbed by water or hemoglobin. This window spans approximately 600 to 1100 nanometers (nm), encompassing visible red light and near-infrared (NIR) light.
AI-generated educational illustration: LLLT device delivering photons into skin tissue layers
Therapeutic Wavelength Ranges
| Wavelength | Type | Tissue Depth | Primary Use |
|---|---|---|---|
| 630 – 700 nm | Visible Red Light | Superficial dermis (~1–2 mm) | Surface wound healing, inflammation |
| 700 – 900 nm | Near-Infrared (NIR) | Deep dermis & subcutaneous (~5–10 mm) | Deeper tissue repair, pain modulation |
| 900 – 1100 nm | Far Near-Infrared | Subcutaneous & muscle | Lymphatic stimulation, deeper structures |
Why LLLT May Help in Hidradenitis Suppurativa
HS involves several biological processes that align closely with the known mechanisms of photobiomodulation. Researchers and clinicians have identified multiple theoretical rationales for why LLLT could benefit HS patients.
HS Biological Targets
- Chronic follicular inflammation and abscess formation
- Impaired wound healing and sinus tract fibrosis
- Elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-17)
- Bacterial colonization (Staphylococcus, anaerobes) in lesions
- Scar tissue and post-inflammatory hyperpigmentation
LLLT Mechanisms That Address These
- Stimulates mitochondrial ATP production via cytochrome c oxidase
- Reduces reactive oxygen species (ROS) and oxidative stress
- Modulates NF-κB inflammatory signaling pathway
- Promotes fibroblast proliferation and collagen synthesis
- Enhances local microcirculation and lymphatic drainage
- Exhibits direct antimicrobial effects at certain wavelengths
AI-generated educational diagram: Cellular mechanism of LLLT / photobiomodulation
What Current Research Shows
LLLT has a stronger evidence base for HS than most other biohacking modalities, though the overall body of evidence is still limited by small sample sizes and short follow-up periods. The most studied laser types for HS are the Nd:YAG (1064 nm) and diode (810 nm) lasers, both of which fall within the near-infrared therapeutic window.
Key findings from available studies include significant reductions in active lesion counts, decreased drainage frequency, and improved patient-reported quality of life scores after structured treatment protocols. Some studies have compared LLLT favorably to standard antibiotic therapy for mild-to-moderate HS.
Nd:YAG laser (1064 nm) has shown significant lesion count reductions in multiple small RCTs for HS
Diode laser (810 nm) demonstrated improvement in Hurley Stage I–II HS in controlled studies
Combination LLLT + standard medical therapy showed additive benefit in observational studies
Home-use red light devices have anecdotal patient reports of reduced flare frequency
Long-term remission data beyond 12 months is not yet established for LLLT in HS
Important Context
Most LLLT studies for HS involve fewer than 50 participants and follow-up periods of 3–12 months. While results are promising, LLLT is not yet included in major dermatology society guidelines (AAD, EADV) as a standard first-line treatment. It is best considered an adjunctive therapy alongside established medical management.
What a Clinical LLLT Protocol Looks Like
LLLT for HS is administered in a clinical setting by a dermatologist or trained laser technician. The following outlines a typical treatment pathway.
AI-generated educational illustration: LLLT administered in a dermatology clinic
Dermatologist Assessment
Confirm HS diagnosis, Hurley stage, and active lesion status. LLLT is typically considered for Hurley Stage I–II.
Device & Wavelength Selection
Clinical Nd:YAG (1064 nm) or diode (810 nm) lasers are most studied. The clinician selects parameters based on lesion depth and skin type.
Treatment Sessions
Typical protocols involve 4–8 sessions spaced 2–4 weeks apart. Each session lasts 15–30 minutes per treatment area.
Response Assessment
Lesion counts, drainage frequency, and pain scores are tracked at each visit. Response is typically assessed at 3 months.
Maintenance Consideration
Some patients require periodic maintenance sessions (every 3–6 months) to sustain improvements.
Typical Cost
$150–$400 per session at a dermatology clinic. Full protocol (4–8 sessions) may cost $600–$3,200 out-of-pocket.
Session Duration
15–30 minutes per treatment area. Multiple body areas may require longer appointments.
Insurance Coverage
Generally not covered by US insurance for HS. Some plans may cover when part of a broader dermatology treatment plan. Always verify in advance.
When LLLT Should Be Avoided or Used With Caution
LLLT is generally safe when performed by a qualified clinician, but there are specific situations where it should be avoided or approached with caution.
Contraindications and Cautions
- Active open wounds or heavily draining lesions (treat after acute phase resolves)
- Photosensitizing medications (tetracyclines, fluoroquinolones, certain biologics - discuss with prescriber)
- Known or suspected skin cancer in the treatment area
- Pregnancy (insufficient safety data for laser therapy)
- Tattoos or dark pigmented lesions in the treatment field
Home Red Light Devices vs. Clinical LLLT
Consumer red light therapy panels and handheld devices have become widely available. While they use similar wavelengths to clinical LLLT, there are important differences in power output, safety, and evidence for HS specifically.
Recommendation: If considering a home device, discuss it with your dermatologist first. Home devices may serve as a complement to clinical treatment for maintenance, but should not replace professional assessment and treatment, particularly for active or severe HS lesions.
Frequently Asked Questions
Is LLLT the same as red light therapy?
They overlap but are not identical. LLLT uses precise, coherent laser light at specific therapeutic wavelengths and power densities. Red light therapy (RLT) typically uses non-coherent LED panels at similar wavelengths. Both work via photobiomodulation, but clinical LLLT devices deliver more targeted and powerful energy. For HS, clinical laser devices (Nd:YAG, diode) have the strongest evidence.
Can LLLT replace biologics or antibiotics for HS?
No. LLLT is an adjunctive therapy, not a replacement for established medical treatments. It may complement antibiotics, biologics, or hormonal therapy by improving wound healing and reducing local inflammation. Always discuss any new therapy with your dermatologist before changing your treatment plan.
How many sessions will I need before seeing results?
Most clinical studies report measurable improvements after 4–6 sessions over 8–12 weeks. Individual responses vary based on Hurley stage, lesion location, and concurrent treatments. Some patients see improvement earlier; others require longer protocols.
Does insurance cover LLLT for HS?
Coverage varies significantly. In the US, LLLT for HS is generally not covered by most insurance plans as a standalone treatment because it is not yet a standard-of-care guideline recommendation. Some plans may cover it when performed by a dermatologist as part of a broader treatment plan. Always verify with your insurer before scheduling.
Is LLLT painful?
Clinical LLLT for HS is generally well-tolerated. Patients may feel mild warmth during treatment. Unlike ablative or surgical lasers, LLLT does not cut or burn tissue. Nd:YAG laser treatments may cause brief discomfort during pulses, particularly over active lesions. Topical anesthetic can be applied if needed.
An Important Perspective on LLLT for HS
Low-level laser therapy represents one of the more evidence-supported adjunctive approaches in the HS biohacking landscape. Unlike many experimental therapies, LLLT has multiple small controlled studies showing measurable benefit, particularly for Hurley Stage I–II disease.
However, it is critical to approach LLLT as a complement to - not a replacement for - established HS treatments. Biologics, antibiotics, hormonal therapy, and surgery remain the foundation of HS management for moderate-to-severe disease. LLLT may help reduce lesion burden and support wound healing, but it does not address the underlying immune dysregulation that drives HS at its root.
This page is for educational purposes only and does not constitute medical advice. Always consult a qualified dermatologist before starting any new therapy for HS.
Medical References
- [1]Waibel JS, et al. Low-level laser therapy for the treatment of hidradenitis suppurativa: a case series. J Drugs Dermatol. 2019;18(9):879-882. PubMed
- [2]Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(1):76-90. PubMed
- [3]Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. PubMed